Replies to post #6899 on GTC Biotherapeutics (fka GTCB)

[waynebio]

Yes look at the market cap!! The current market cap value for GTCB is $20mm lower than the value of the tax write off on all the net losses incurred to date. Unless either GTCB goes bankrupt with $80+mm of debt or GTCB starts accumulating hundreds of millions of net income, there will be tax write off value to GTCB. I think this alone is proof that the stock price is too low. This is further self reinforcing pressure on the stock price since anticipated dilution to raise cash at too low of a price will require more shares to need to be issued than otherwise would have.

Does anyone know if most small biotechs have poison pills in place?

[zeeuw]

That has nothing to do with that white paper conclusion. In my opinion transgenics, with ATryn being the first approved product, is simple a proof of concept. Will the market accept ATryn? How sustainable, safe and reliable will the product behave? That are the real questions and these questions are also the risk of transgenics. In my vision BP just waits and see. Some maller companies take the gamble (LEO en LFB).
Meanwhile we see encouraging developments: LFB extends her cooperation with GTC and there is more to come, I believe. Maybe in the very near future LFB will extend their share in GTC to, let's say 49%, with new shares. A solution with a tear and a smile. In these circumstances I would go for it when my name was Cox. But what about Genzyme?

Zeeuw